美国马萨诸塞州，中国北京--2020年12月7日，北京云顶国际基因生物技术有限公司（简称“云顶国际”）宣布，与Xencor, Inc.（简称“Xencor”）完成RenMab^®/RenLite™全人抗体小鼠平台授权使用协议签订。云顶国际与Xencor在临床前药理药效研究方面有良好的合作，此次全人抗体小鼠的使用授权将进一步扩大双方的合作范围，加强Xencor抗体药物的研发实力，以满足全球对有效生物疗法日益增长的需求。

Wakefield MA, Beijing China — Dec 7, 2020 — Beijing Biocytogen Co., Ltd. , Biocytogen Boston Corp (collectively as “Biocytogen”) announced today that they have reached an agreement with Xencor, Inc., for the licensing of Biocytogen’s fully human antibody RenMab™/RenLite™ Mouse platform to enhance Xencor’s monoclonal antibody drug discovery research.

The leading platform for fully human antibody generation

The RenMab™ Mouse was developed using Biocytogen’s unique chromosome engineering technique. In this model, the Ig genes that encode for antibody variable domains of heavy and κ light chains are fully replaced by human corresponding Ig genes . The RenLite™ Mouse is a genetically engineered model with complete humanization in the variable region of the heavy chains, while maintaining a single human light chain. These models can be used to fast generate and screen fully human antibody hits and thus identify therapeutic candidates with high affinities, specificities, and diversities more efficiently than by using other available technology platforms.

Xencor is a leading clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. Xencor and Biocytogen have collaborated on preclinical pharmacology studies, and Xencor moved forward with the new licensing agreement after Biocytogen released RenLite™’s robust validation data.

"We are excited to begin this collaboration,” said Dr. John Desjarlais, Xencor’s CSO. “We anticipate the RenMab and RenLite platforms will extend our bispecific antibody discovery and look forward to working with the team at Biocytogen."

The agreement, reached on October 27,  includes licenses for the RenMab™ and RenLite™ mouse platforms and Biocytogen’s ongoing support of Xencor’s drug development efforts to help meet the increasing global demand for effective biologic therapies.

“We are delighted that Xencor has selected the Biocytogen RenMab™/RenLite™ mice for their development of novel fully human antibody candidates,” said YueLei Shen, Founder and CEO of Biocytogen. “We are highly confident that the combination of our fully-humanized mouse model and Xencor’s proven expertise in drug discovery and development will provide the ideal collaboration for the Xencor’s discovery of clinically-relevant antibodies.”

The RenMab™ and RenLite™ antibody platforms are available for licensing to pharmaceutical and biotechnology partners seeking to streamline their antibody discovery workflow. For more information on RenMab™ and RenLite™, visit https://renmab.com.

About Beijing Biocytogen Co., Ltd.

Biocytogen is a global biotech company that drives the research and development of new drugs with innovative technologies. The company is committed to becoming a global headstream of new drugs and bringing the benefits to the patients around the world as its mission. Biocytogen has established a highly integrated antibody drug discovery platform based on a series of genetically-modified animal models. Biocytogen has developed the RenMab™ mouse model for fully human antibodies production with robust humoral responses, highly diverse antibody repertoire and superior affinity.

Biocytogen has launched a pioneering antibody drug development plan (Project Integrum https://biocytogen.com/renmab-mouse/project-integrum/) to tackle difficult targets based on the immunization of RenMab™ knockout mice. Nearly 1,500 targets knockout mouse strains will be generated within 2 years for antibody discovery. Moreover, with the knockout immunization strategy, antibody hits cross-reacting with different species shall be more likely to be generated for better translational efficacy and toxicity evaluation.

With the world-class expertise in genetically-engineered animal development and maintenance with large-scale animal breeding capacity, antibody discovery, and preclinical pharmacology services, the company provides seamless integrated antibody discovery services to the biomedical community for a true one-stop solution from target to IND application and has built its collaboration with more than 2,000 partners worldwide, including over 70% of top 20 MNCs.